Finding Key To Cancer Drug Gleevec's Limitations

Researchers have learned why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease from returning if treatment ends. The team is now combining imatinib with other drugs in mouse studies to find ways to sensitize resistant leukemia-initiating cells to imatinib and enhance its power.

Read the whole article on Science Daily

More from Science Daily